Division of Global New Drug Development, Enzychem Lifesciences, Daejeon 34013, Republic of Korea.
Division of Biomaterials Research, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Radiat Res. 2021 Jul 1;196(1):55-65. doi: 10.1667/RADE-20-00288.1.
The growing risk of accidental radiation exposure due to increased usage of ionizing radiation, such as in nuclear power, industries and medicine, has increased the necessity for the development of radiation countermeasures. Previously, we demonstrated the therapeutic potential of the acetylated diacylglycerol, 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG), as a radiation countermeasure by mitigating radiation-associated mortality and hematopoietic acute radiation syndrome (H-ARS) in BALB/c mice after a lethal dose (LD70/30) of gamma-ray total-body irradiation (TBI). In this study, we show that PLAG mitigates symptoms of H-ARS, as characterized by mature blood cell recovery and restoration of bone marrow cellularity, by regulating systemic inflammation. Log-rank test demonstrated that high levels of WBCs, lymphocytes and neutrophils on day 10 post-TBI resulted in significantly improved survival rate. PLAG significantly enhanced the nadir values of all major blood cell types as well as bone marrow cellularity. A single TBI at LD70/30 induced an immediate increase in the blood levels of CXCL1 (12.5 fold), CXCL2 (1.5 fold), IL-6 (86.9 fold), C-reactive protein (CRP; 1.3 fold) and G-CSF (15.7 fold) at 6 h post-TBI, but the cytokine levels returned to baseline level afterward. When the irradiated mice started to die around 15 days post-TBI, they exhibited a second surge in blood levels of CXCL1 (49.3 fold), CXCL2 (87.1 fold), IL-6 (208 fold), CRP (3.6 fold) and G-CSF (265.7 fold). However, PLAG-treated groups showed a significant decrease in these same blood levels (P < 0.001). Considering the inverse correlation between inflammatory cytokine levels and hematological nadirs, PLAG exerts its therapeutic effects on H-ARS by regulating inflammatory cytokine production. These data suggest that PLAG has high potential as a radiation countermeasure to mitigate H-ARS after accidental exposure to radiation.
由于电离辐射(如核能、工业和医学)的使用增加,意外辐射暴露的风险不断增加,这增加了开发辐射对策的必要性。此前,我们通过减轻 BALB/c 小鼠致死剂量(LD70/30)γ射线全身照射(TBI)后与辐射相关的死亡率和造血急性辐射综合征(H-ARS),证明了乙酰化二酰基甘油 1-棕榈酰基-2-亚油酰基-3-乙酰基-rac-甘油(PLAG)作为辐射对策的治疗潜力。在这项研究中,我们表明 PLAG 通过调节全身炎症来减轻 H-ARS 的症状,其特征是成熟血细胞的恢复和骨髓细胞的恢复。对数秩检验表明,TBI 后第 10 天白细胞、淋巴细胞和中性粒细胞的高水平导致生存率显著提高。PLAG 显著提高了所有主要血细胞类型以及骨髓细胞的最低点值。单次 TBI 在 LD70/30 下,在 TBI 后 6 小时即刻引起血液中 CXCL1(12.5 倍)、CXCL2(1.5 倍)、IL-6(86.9 倍)、C 反应蛋白(CRP;1.3 倍)和 G-CSF(15.7 倍)水平的急剧增加,但此后细胞因子水平恢复到基线水平。当受照射的小鼠在 TBI 后约 15 天开始死亡时,它们的血液中 CXCL1(49.3 倍)、CXCL2(87.1 倍)、IL-6(208 倍)、CRP(3.6 倍)和 G-CSF(265.7 倍)的水平再次飙升。然而,PLAG 治疗组这些相同的血液水平明显下降(P < 0.001)。考虑到炎症细胞因子水平与血液学最低点之间的反比关系,PLAG 通过调节炎症细胞因子的产生对 H-ARS 发挥治疗作用。这些数据表明,PLAG 作为一种辐射对策,在意外暴露于辐射后具有减轻 H-ARS 的巨大潜力。